GAN & LEE PHARMACEUTICALS. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.57 CNY | -1.08% |
|
-3.82% | -26.74% |
| 09-06 | Gan & Lee Pharmaceuticals. announces an Equity Buyback for CNY 300 million worth of its shares. | CI |
| 09-05 | Gan & Lee Pharmaceuticals. authorizes a Buyback Plan. | CI |
Sales 2023 by Business Segment
Sales 2023 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
Medical Device Research and Development | |||||||
Development, Production and Sales of Insulin and Related Products | 2.9B | 3.36B | 3.61B | 1.71B | 2.61B | ||
Total Assets | 6.03B | 9.51B | 10.85B | 10.61B | 11.72B | ||
Interest Expense | - | - | -965K | -776K | -552K | ||
Income Tax Expense | 230M | 215M | 243M | -143M | -34.09M | ||
CAPEX | -407M | -582M | -692M | -983M | -553M | ||
EBT | 1.4B | 1.45B | 1.7B | -582M | 306M | ||
D&A | 114M | 158M | 182M | 195M | 219M | ||
Operating Income | 1.4B | 1.45B | 1.7B | -569M | 315M | ||
Net Income | 1.17B | 1.23B | 1.45B | -440M | 340M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
China | - | 3.27B | 3.36B | 1.44B | 2.18B | ||
International | 121M | 92.81M | 256M | 276M | 426M | ||
Mainland China | 2.77B | - | - | - | - |
- Stock Market
- Equities
- 603087 Stock
- Financials Gan & Lee Pharmaceuticals.
- Business Segments
MarketScreener is also available in this country: United States.
Switch edition